ACA A.I CyberSecurity Scoring
15/01/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Agilent Cell Analysis in 2026.
No incidents recorded for Agilent Cell Analysis in 2026.
No incidents recorded for Agilent Cell Analysis in 2026.
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra
Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.
Amgen harnesses the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller and longer. We helped establish the biotechnology industry, and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. Amgen is one of 30 companies comprising the Dow Jones Industrial Average®, and part of the Nasdaq-100 Index®. In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes. For more information, visit Amgen.com and follow us on X, LinkedIn, Instagram, TikTok, YouTube and Threads. 🔗 Community Guidelines: https://wwwext.amgen.com/community-guidelines 🔗Global Privacy Statement Directory: www.amgen.com/dp Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.
NIH is the only agency of its kind. We impact the health of the country and the world through unique and innovative medical research. Did you know that NIH is the largest public funder of biomedical research in the world, investing more than $32 billion a year to enhance life, and reduce illness and disability? NIH funded research has led to breakthroughs and new treatments, helping people live longer, healthier lives, and building the research foundation that drives discovery. Whether you are graduating with a bachelor's degree, working on your doctoral degree, entering the workforce for the first time, or changing careers, NIH offers a place for you to start and plenty of room to grow your career. When you join us, you’re not just advancing your career — you’re driving the health of our country forward. Official LinkedIn Account of the NIH. Privacy policy: http://go.usa.gov/x9svN Comment policy: https://bit.ly/3G6xq94 Engagement ≠ endorsement
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
At Charles River, we are guided by our strong purpose—to create healthier lives—which centers around the patients who rely on the therapeutics we help to develop, the animals in our care, to our planet, and to the passionate and skilled people who are at the heart of our organization and make it all possible. #DrugDiscovery #Biotech #Biotechnology #Pharmaceuticals #CRL
Latest updates, reports, and threat intel affecting the global network.
A Delaware federal court ruled that laboratory equipment company Agilent Technologies couldn't collect damages for any alleged infringement...
Agilent's new 21 CFR Part 11 software brings secure logins, e-signatures and audit trails to RTCA eSight, enabling use in GMP manufacturing...
The facility, serving as a hub of Biopharma, offers solutions across chromatography, mass spectrometry, cell analysis, and lab informatics. US-Based Agilent...
The NUS-Agilent Center of Excellence (CoE) in Cell Metabolism, a scientific collaboration to advance cardiovascular and metabolic disease translational...
The new ProteoAnalyzer system from Agilent was announced at the annual PepTalk Conference.
Most of the reductions, which equal about 2% of the company's global workforce, will be completed in the first quarter, Agilent said.
The appointment comes less than three months after former CEO Francis deSouza stepped down following a proxy battle.
Some of the challenges associated with fast, real-time testing, comprehensive analysis of samples, and post-processing of the data do exist but continue to...
The new system has a significantly increased throughput, capable of scanning one 96 well microplate at 10X magnification in only 3 to 4 minutes.
ClipBucket v5 is an open source video sharing platform. Prior to version 5.5.3 - #133, a normal authenticated user can edit another user's video subtitles because of a lack of authorization. They can upload subtitles, edit their name or delete them. This issue has been patched in version 5.5.3 - #133.
ClipBucket v5 is an open source video sharing platform. Prior to version 5.5.3 - #132, any authenticated user who can upload videos can add multiple subtitles from different files and change their title (English, Spanish...). The POST /actions/subtitle_edit.php request used to change their title includes a number parameter which is vulnerable to SQL Injection. A boolean-based blind SQL injection can be used to exfiltrate sensitive data. This issue has been patched in version 5.5.3 - #132.
ClipBucket v5 is an open source video sharing platform. Prior to version 5.5.3 - #129, the actions/progress_video.php endpoint is vulnerable to blind SQL injection. Any unauthenticated user can exploit the ids parameter to execute SQL queries and exfiltrate sensitive data. This issue has been patched in version 5.5.3 - #129.
ClipBucket v5 is an open source video sharing platform. Prior to version 5.5.3 - #140, ClipBucket's Remote Play feature allows any authenticated user to add a video by importing an external URL as the source. Some shell commands are run with the URL as a parameter. The URL is concatenated directly into shell commands without escaping then executed, so any shell metacharacter in the URL is interpreted. This results in arbitrary command execution. This issue has been patched in version 5.5.3 - #140.
An authenticated format string vulnerability exists in the ONVIF service of Tapo C110 v2 due to improper handling of user-controlled input. Externally controlled data is interpreted as a format string, which can be used to manipulate stack memory, including control flow data such as return addresses. A remote authenticated attacker may redirect execution flow to existing internal functions, triggering an unauthorized factory reset, leading to loss of configuration, deletion of stored credentials and service disruption.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.